Infigratinib receives accelerated approval from the FDA for metastatic cholangiocarcinoma

Share This Post

August 2021: Infigratinib (Truseltiq, QED Therapeutics, Inc.), a kinase inhibitor, has been granted accelerated approval by the Food and Drug Administration for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

The FDA also approved FoundationOne® CDx (Foundation Medicine, Inc.) as a companion diagnostic device for infigratinib treatment in patients with FGFR2 fusion or additional rearrangements.

CBGJ398X2204 (NCT02150967), a multicenter open-label single-arm trial with 108 patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement as verified by local or central tests, demonstrated efficacy. Infigratinib 125 mg orally once daily for 21 days, followed by 7 days off therapy, was given to patients in 28-day cycles until disease progression or unacceptable toxicity.

Overall response rate (ORR) and duration of response (DoR) were the primary efficacy outcome measures, as established by a blinded independent central review in accordance with RECIST 1.1. With 1 complete response and 24 partial responses, the ORR was 23% (95 percent CI: 16, 32). The average DoR was 5 months (95 percent CI: 3.7, 9.3). Eight of the 23 responders kept their answer for six months or longer.
Hyperphosphatemia, increased creatinine, nail toxicity, stomatitis, dry eye, fatigue, alopecia, palmar-plantar erythrodysesthesia syndrome, arthralgia, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, diarrhoea, dry skin, decreased appetite, vision blurred, and vomiting were the most common adverse reactions (incidence 20%). Hyperphosphatemia and retinal pigment epithelial detachment are major hazards, and patients should be monitored for these side effects during treatment.

You may like to read : Cancer treatment in India

In 28-day cycles, the recommended infigratinib dose is 125 mg orally once day on an empty stomach for 21 days, followed by 7 days off medication.


Check details here.

Take second opinion on cholangiocarcinoma treatment

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form

Start chat
Need help with cancer treatment?

Welcome to CancerFax.

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

let us know what services would you like to take?

1) Travel abroad for cancer treatment
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation